Ethernet-based lighting-architecture : Image stabilization for high-resolution light functions

Single pair Ethernet in combination with Ethernet endpoints provides a scalable basis for the direct control of sensors and actuators in zonal vehicle networks. As recently shown, this approach is also ideal for driving high-resolution light functions. The ability to transmit different parallel data streams to actuators opens a wide field for new applications. Here, we show a method for stabilising high-resolution light projections in driving operation. The stabilization of the light image is based on an inertial measurement unit that records vehicle movements in real-time. An algorithm in a central control unit continuously calculates correction values for the position and distortion compensation of the light distribution and sends this data to the lamp via Ethernet, preferably 10BASE-T1S. Two methods are combined in a proof of concept: predictive correction with video data rate and image shifting in the headlamp’s frame buffer at high frequency

Carrier-Envelope Offset Frequency Stabilization of a Thin-Disk Laser Oscillator via Depletion Modulation

We present a novel concept for the stabilization of the carrier-envelope offset (CEO) frequency of femtosecond pulse trains from thin-disk laser oscillators by exploiting gain depletion modulation in the active gain region. We shine a small fraction of the laser output power back onto the thin disk allowing the population inversion in the gain medium to be controlled. We employ this technique in our home-built Kerr-lens mode-locked Yb:YAG thin-disk laser and benchmark the performance against the proven technique of pump current modulation for CEO stabilization, showing that the two techniques have equivalent performance. The new method which only requires an additional AOM demonstrates a scalable and cost-effective method for CEO stabilization of high-power laser oscillators

A 19-year-old patient with atypical chronic myeloid leukemia

The International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (NCT01374360) was initiated to optimize patient management by collecting data regarding disease burden, progression, and clinical outcomes. Herein, we report updated baseline demographics, clinical characteristics, disease burden data, and observed trends regarding clone size in the largest cohort of Registry patients. Patients with available data as of July 2017 were stratified by glycosylphosphatidylinositol (GPI)-deficient granulocyte clone size (< 10%, ≥ 10%-< 50%, and ≥ 50%). All patients were untreated with eculizumab at baseline, defined as date of eculizumab initiation or date of Registry enrollment (if never treated with eculizumab). Outcomes assessed in the current analysis included proportions of patients with high disease activity (HDA), history of major adverse vascular events (MAVEs; including thrombotic events [TEs]), bone marrow failure (BMF), red blood cell (RBC) transfusions, and PNH-related symptoms. A total of 4439 patients were included, of whom 2701 (60.8%) had available GPI-deficient granulocyte clone size data. Among these, median clone size was 31.8% (1002 had < 10%; 526 had ≥ 10%-< 50%; 1173 had ≥ 50%). There were high proportions of patients with HDA (51.6%), history of MAVEs (18.8%), BMF (62.6%), RBC transfusion (61.3%), and impaired renal function (42.8%). All measures except RBC transfusion history significantly correlated with GPI-deficient granulocyte clone size. A large proportion of patients with GPI-deficient granulocyte clone size < 10% had hemolysis (9.7%), MAVEs (10.2%), HDA (9.1%), and/or PNH-related symptoms. Although larger GPI-deficient granulocyte clone sizes were associated with higher disease burden, a substantial proportion of patients with smaller clone sizes had history of MAVEs/TEs

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib upfront (300, 400, 500 mg/m(2), respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective